

^aI. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany; ^bFaculty of Medicine, Institute for Molecular Cell Biology, Universitätsklinikum Homburg/Saar, Universität des Saarlandes, Homburg/Saar, Germany; ^cInstitute for Biochemistry and Molecular Biology, Ulm University, Medical Faculty, Ulm, Germany; ^dInternational Graduate School in Molecular Medicine Ulm, Ulm University, Ulm, Germany; ^eInstitute of Medical Microbiology, Immunology, and Hygiene, Technische Universität München, Munich, Germany; ^fClinical Cooperation Group "Immune Monitoring," Helmholtz Center Munich, Neuherberg, Germany; ^gDZHK (German Centre for Cardiovascular Research) - Partner Site Munich Heart Alliance, Munich, Germany

Correspondence: Alessandra Moretti, Klinikum rechts der Isar – Technische Universität München, I. Medical Department – Molecular Cardiology, Ismaninger Straße 22, 81675 Munich, Germany. Telephone: 49-89-4140-6907; Fax: 49-89-4140-4900; e-mail: amoretti@mytum.de; or Michael Kühn, Institute for Biochemistry and Molecular Biology, Ulm University, Albert-Einstein-Allee 11, 89081 Ulm, Germany. Telephone: 49-731-500-23283; Fax: 49-731-500-23277; e-mail: michael.kuehl@uni-ulm.de

Received April 30, 2014; accepted for publication November 8, 2014; ; first published online in *STEM CELLS EXPRESS* December 19, 2014.

© AlphaMed Press
1066-5099/2014/\$30.00/0
<http://dx.doi.org/10.1002/stem.1923>

This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

[The copyright line for this article was changed on August 23, 2019, after original publication.]

Direct Nkx2-5 Transcriptional Repression of *Isl1* Controls Cardiomyocyte Subtype Identity

TATJANA DORN,^a ALEXANDER GOEDEL,^a JASON T. LAM,^a JESSICA HAAS,^a QINGHAI TIAN,^b FRANZISKA HERRMANN,^{c,d} KARIN BUNDSCHU,^c GERGANA DOBREVA,^a MATTHIAS SCHIEMANN,^{e,f} RALF DIRSCHINGER,^a YANCHUN GUO,^{c,d} SUSANNE J. KÜHL,^c DANIEL SINNECKER,^a PETER LIPP,^b KARL-LUDWIG LAUGWITZ,^{a,g} MICHAEL KÜHL,^c ALESSANDRA MORETTI^{a,g}

Key Words. *Isl1* • Nkx2-5 • Cardiac differentiation • Cardiac progenitors • Heart development • Embryonic stem cells

ABSTRACT

During cardiogenesis, most myocytes arise from cardiac progenitors expressing the transcription factors *Isl1* and *Nkx2-5*. Here, we show that a direct repression of *Isl1* by *Nkx2-5* is necessary for proper development of the ventricular myocardial lineage. Overexpression of *Nkx2-5* in mouse embryonic stem cells (ESCs) delayed specification of cardiac progenitors and inhibited expression of *Isl1* and its downstream targets in *Isl1*⁺ precursors. Embryos deficient for *Nkx2-5* in the *Isl1*⁺ lineage failed to downregulate *Isl1* protein in cardiomyocytes of the heart tube. We demonstrated that *Nkx2-5* directly binds to an *Isl1* enhancer and represses *Isl1* transcriptional activity. Furthermore, we showed that overexpression of *Isl1* does not prevent cardiac differentiation of ESCs and in *Xenopus laevis* embryos. Instead, it leads to enhanced specification of cardiac progenitors, earlier cardiac differentiation, and increased cardiomyocyte number. Functional and molecular characterization of *Isl1*-overexpressing cardiomyocytes revealed higher beating frequencies in both ESC-derived contracting areas and *Xenopus* *Isl1*-gain-of-function hearts, which associated with upregulation of nodal-specific genes and downregulation of transcripts of working myocardium. Immunocytochemistry of cardiomyocyte lineage-specific markers demonstrated a reduction of ventricular cells and an increase of cells expressing the pacemaker channel *Hcn4*. Finally, optical action potential imaging of single cardiomyocytes combined with pharmacological approaches proved that *Isl1* overexpression in ESCs resulted in normally electrophysiologically functional cells, highly enriched in the nodal subtype at the expense of the ventricular lineage. Our findings provide an *Isl1*/*Nkx2-5*-mediated mechanism that coordinately regulates the specification of cardiac progenitors toward the different myocardial lineages and ensures proper acquisition of myocyte subtype identity. *STEM CELLS* 2015;33:1113–1129

INTRODUCTION

The mammalian heart is composed of a complex set of muscle and nonmuscle cells that arise from multipotent progenitors in the first and second heart field (FHF and SHF) [1, 2]. Despite extensive study of heart development using genetically modified mouse models and lineage tracing experiments, a complete and accurate picture of the molecular pathways underpinning heart development is still elusive. Little is known about the control of the signaling networks that regulate the transition from progenitors toward differentiated myocardial cells and how these networks are perturbed in congenital and adult forms of heart disease.

The LIM-homeodomain transcription factor *Isl1* is a key regulator of SHF progenitors and is required for survival, proliferation, and migration of these cells into the FHF-derived primitive heart tube, resulting in its elongation

and further morphogenesis [3]. However, recent reports suggest that *Isl1* is likely to be pan-cardiac progenitor marker, being expressed in both cardiac progenitor fields in early development [4, 5]. FHF and SHF progenitors also express NK2 transcription factor related, locus 5 (*Nkx2-5*), a pivotal regulator of the cardiac lineage [6–8]. While *Isl1* is mostly restricted to a progenitor cell state in the heart and is downregulated upon myocardial differentiation, *Nkx2-5* is expressed throughout cardiac development, with high levels in embryonic differentiated cardiomyocytes [9, 10]. In *Nkx2-5* knockout mutants, the formation of the heart tube is severely affected, and proliferation of cardiac progenitor cells is altered, showing the key regulatory role of this transcription factor. In addition, genes normally expressed in the SHF and downregulated upon differentiation into myocardium, including *Isl1*, fail to undergo this downregulation [4].

In the present study, we describe an *Isl1*/*Nkx2-5*-mediated mechanism that regulates cardiac progenitor cell fate by initiating differentiation into either a working myocardial or a sinoatrial node (SAN) cell type. Using genetic mouse and *Xenopus* models as well as molecular analyses in *Nkx2-5*- and *Isl1*-overexpressing mouse embryonic stem cells (ESCs), we demonstrate that a direct repression of *Isl1* transcription by *Nkx2-5* is necessary for proper specification and maturation of the ventricular myocardial lineages.

MATERIALS AND METHODS

Mice

Nkx2-5^{f/f} mice were generously provided by Kenneth R. Chien (Karolinska Institute, Solna, Sweden) [11]. *Isl1*-Cre mice were generously provided by Sylvia Evans (University of California-San Diego, La Jolla, CA) [12]. Mice are in a mixed 129 × C57Bl/6 background.

Xenopus Experiments

Xenopus embryos were generated by in vitro fertilization and staged as described [13]. For gain of function experiments, *isl1* RNA was injected either unilaterally (1 ng per embryo for marker gene analysis by whole-mount in situ hybridization [ISH]) or bilaterally (2 ng per embryo for heart rate and *Isl1* downstream target gene analysis by reverse transcription polymerase chain reaction (RT-PCR)) into dorso-vegetal blastomeres of eight-cell stage embryos to target cardiac tissue. To control proper injections, 500 pg green fluorescent protein (*GFP*) mRNA were coinjected as a lineage tracer. In situ antisense RNA probes were generated as delineated earlier [14, 15]. Whole-mount in situ experiments were performed at stage 20 and 28 as described [16] and expression of *Isl1* downstream target genes was analyzed on pooled heart explants isolated at stage 24.

Cell Culture

ESCs were maintained in standard ESC medium (Dulbecco's modified Eagle's medium [DMEM; Life Technologies, Darmstadt, Germany, <http://www.lifetechnologies.com/de/de/home.html>], supplemented with 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 0.1 mM β-mercaptoethanol, 50 U/ml penicillin, 50 μg/ml streptomycin, 15% fetal bovine serum [FBS], and 0.1 μg/ml leukemia inhibitory factor [LIF; Millipore, Hessen, Germany, <http://www.merck-millipore.com/DE/de/>]) on irradiated murine embryonic fibroblasts (MEFs). HEK293T and C3H 10 T1/2 cells were cultured in DMEM and basal medium Eagle (Life Technologies), respectively, supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 10% FBS. All cells were kept at 37°C and 5% CO₂.

Genetically Modified ESCs and In Vitro Differentiation of ESCs

Mouse *Isl1* and *Nkx2-5* cDNA were cloned into the lentiviral transfer plasmid pRRlsin18.PPT.PGK.IRES.GFP. Lentiviruses were produced in HEK293T cells by transient cotransfection of lentiviral transfer vector, CMVΔR8.74 packaging plasmid and VGV.G envelope plasmid using Fugene HD (Promega, Mannheim, Germany, <http://www.promega.de/en/>). Viral

supernatants were harvested after 48 hours and used for infection of *Isl1-nlacZ* knock-in R1 ESCs in the presence of 8 μg/ml polybrene. One week after infection, ESCs were flow cytometry-sorted for eGFP expression. A second *Isl1*-overexpressing ESC line was generated using a plasmid-based approach in E14 ESCs as described earlier [17] providing identical results to the lentiviral approach.

ESCs were differentiated as EBs generated by aggregation of MEF-depleted 6×10^4 cells per milliliter in ESC medium (without LIF) in low attachment plates coated with 5% poly(2-hydroxyethyl methacrylate) (Sigma-Aldrich, Schnellendorf, Germany, <http://www.sigmaaldrich.com/germany.html>) or by the hanging drop method as described previously [17]. For the analysis of beating activity and lacZ staining, day 2 EBs were plated onto gelatine-coated 24- or 6-well plates. The percentage of wells containing beating EBs was determined during days 7 and 14 of EB differentiation. Beating frequency was measured at day 14 of EB differentiation as the number of beats per minute and statistically evaluated with Prism 5 (GraphPad Software). To derive single cardiomyocytes for immunofluorescence staining, beating areas from day 16 EBs were manually dissected, dispensed into single cells with 1.5 mg/ml collagenase II (290 U/ml; Worthington CLS, Lakewood, NJ, <http://www.worthington-biochem.com/default.html>) and transferred onto fibronectin-coated coverslips in six-well plates.

Western Blotting

Western blotting was performed using standard protocols, with the following antibodies: anti-*Isl1* (39.4D5; Developmental Studies Hybridoma Bank, Iowa City, Iowa, <http://dshb.biology.uiowa.edu/>), anti-*Nkx2-5* (N-19; Santa Cruz Biotechnology, Heidelberg, Germany, <http://www.scbt.com/>), and anti-β-actin (ab8227; Abcam, Cambridge, UK, <http://www.abcam.com/>).

LacZ, Immunocytochemistry, and Immunohistology

LacZ staining was performed on plated EBs after fixation with 0.2% glutaraldehyde, incubation in X-Gal solution containing 1.25 mM K₃(Fe(CN)₆), 1.25 mM K₄(Fe(CN)₆), 2 mM MgCl₂, 0.02% Nonidet P-40, and 0.25 mg/ml X-Gal in phosphate buffered saline. For each differentiation experiment and time point, nuclear lacZ positive cells were counted in 20 EBs from each of the transgenic mouse ESC lines by investigators blinded to the genotype of the cells using a ×40 objective in bright field. To inhibit proliferation, plated EBs were treated with mitomycin C (2 μg/ml; Sigma-Aldrich) at day 3 of differentiation, and lacZ positive cells were counted on the two following days. For immunofluorescence analysis, day 14 EBs or day 19 cardiomyocytes were fixed in 4% paraformaldehyde and subjected to specific immunostaining using following primary antibodies: cTnT (1:300; Abcam), α-actinin (1:300; Sigma-Aldrich), and *Isl1* (1:150; Developmental Studies Hybridoma Bank). Immunocytochemistry for Mlc2a (1:200; Synaptic Systems, Goettingen, Germany, <http://www.sysy.com/>), Mlc2v (1:100; Proteintech, Manchester, UK, <http://www.ptglab.com/>; 1:100; Synaptic Systems), and Hcn4 (1:100; Abcam) was performed on dissociated cardiomyocytes at day 30 of differentiation. Phalloidin-AlexaFluor-594-conjugate (1:100; Life Technologies) was used to stain F-actin. For immunohistological analysis of mouse embryonic hearts, cryosections of 6-μm thickness were probed for *Isl1*, cTnT (1:1000; EPR3696; Abcam), and phospho-

histone H3 (Ser10) (PHH3)-AlexaFluor-647 (1:100; Cell Signaling Technologies, Leiden, Netherlands, <http://www.cellsignal.com/>). Nuclei were visualized with 4',6-diamidino-2-phenylindole (DAPI) (Dianova, Hamburg, Germany, <http://www.dianova.com/>). AlexaFluor-488-, AlexaFluor-594-, AlexaFluor-647- (1:500; Life Technologies), and Cy3-conjugated (1:500; Dianova) secondary antibodies specific to the appropriate species were used. Images were captured using either a DMI6000-AF6000 Leica or a BX60 Olympus fluorescence microscope or a Leica TCS SP5 II confocal laser-scanning microscope.

Flow Cytometry

For β -galactosidase (β -gal)-based flow cytometry sorting, day 4 EBs were dissociated with 0.25% trypsin and incubated for 2 min with 1 mM C_{12} FDG (Molecular Probes, Darmstadt, Germany, <http://www.lifetechnologies.com/de/de/home.html>) at 37°C. Isolation of C_{12} FDG⁺ cells was performed using FACSAria (BD, Heidelberg, Germany, <http://www.bd.com/de/>), and data were analyzed with FACSDiva software (BD). For Ki67 proliferation flow cytometry analysis, FDG⁺ sorted cells from 5-day-old EBs were fixed with 3.7% formaldehyde, blocked, and incubated with primary Ki67 antibody (1:100; Abcam). Subsequently, AlexaFluor-647-conjugated secondary antibody specific to rabbit was used (1:500; Life Technologies). Flow cytometry was performed on a MoFlo XDP (Beckman-Coulter, Krefeld, Germany, <http://www.beckmancoulter.de/>), and data were analyzed using Kaluza software (Beckman-Coulter). For cTnT flow cytometry analysis, day 14 EBs were dissociated with collagenase, fixed with 3.7% formaldehyde, blocked and incubated with primary cTnT antibody (0.4 μ g/ml, clone 13-11; Thermo Scientific, Schwerte, Germany, <http://www.thermoscientificbio.com/>). For detection, AlexaFluor-647-conjugated secondary antibody specific to mouse was used (1:500; Life Technologies). Samples were measured on the FACSCalibur (BD). Data were analyzed using CellQuest software (BD).

Chromatin Immunoprecipitation Assay

Chromatin immunoprecipitation (ChIP) assay was performed on day 4 EBs as previously described [18]. Cloning and sequencing of 1000 DNA fragments precipitated by the anti-Is1 antibody, followed by stringent validation [19], identified over 600 genes, including the two previously characterized targets of *Is1*, *Mef2c* and *Gata6* [20]. DNA enrichment of the precipitated fragments was measured by quantitative PCR (qPCR) for selected genes. Details on the ChIP protocol can be found in the Supporting Information Methods.

Semiquantitative and Quantitative RT-PCR

Total RNA was extracted with the RNA Pure Kit (Peqlab, Erlangen, Germany, <http://www.peqlab.de/wcms/de/index.php>) or Absolutely RNA Kit (Agilent Technologies, Waldbronn, Germany, <http://www.agilent.com/home>). cDNA was synthesized with Superscript II (Life Technologies) and subjected to semiquantitative RT-PCR using Phire Hot Start II DNA Polymerase (Finnzymes, Schwerte, Germany, <http://www.thermoscientificbio.com/finnzymes/>). For quantitative RT-PCR (qRT-PCR) analysis, cDNA was synthesized with High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Darmstadt, Germany, <http://www.lifetechnologies.com/de/de/home.html>). One microliter of the RT reaction together with the Power SYBR Green or

TaqMan Universal PCR Master Mix (Applied Biosystems) was used for the subsequent qPCR. Gene expression levels were normalized to *Gapdh*. Primer sequences and TaqMan probes are provided in Supporting Information Table S1. The results illustrated in Figure 3A were obtained using a customized qRT-PCR TaqMan Low Density Array (IMGM Laboratories, Martinsried, Germany, <http://www.imgm.com/>).

Luciferase Assay

A -4.5 to 8.0 kb *Is1* enhancer region encompassing three Nkx2-5 binding sites was inserted into a minimal-promoter-containing luciferase reporter plasmid pgl4.24 (Promega). Luciferase assays were performed in C3H 10 T1/2 cells as described [18].

Electrophoretic Mobility Shift Assay

HEK293T cells were transiently transfected with pcDNA-Nkx2-5 plasmid using SuperFect Transfection Reagent (Qiagen, Hilden, Germany, <http://www.qiagen.com/de/>) and 48 hours later nuclear protein extracts were prepared with NE-PER Nuclear and Cytoplasmic Extraction Reagent Kit (Thermo Scientific). Double stranded DNA probes, generated by annealing of sense and antisense oligonucleotides, were biotin-labeled using Biotin 3' End DNA Labeling Kit (Thermo Scientific) and Nkx2-5 DNA-binding activity was determined by the non-radioactive LightShift Chemiluminescent electrophoretic mobility shift assay (EMSA; Thermo Scientific). For blotting, a Biotinylated B nylon membrane (Thermo Scientific) was used. Signals were detected by applying stabilized Streptavidin Horseradish Peroxidase Conjugate and luminol solution (Thermo Scientific). The sequences of EMSA oligonucleotides are listed in Supporting Information Table S1.

In Situ Hybridization in Mouse Embryos

Whole-mount RNA in situ hybridization was carried out as described [3]. *Is1*- and *Nkx2-5*-cDNA-pCR-BluntII-TOPO clones were used to synthesize antisense and sense RNA probes. *Tbx5* in situ probe was kindly provided by Sylvia Evans (University of California-San Diego, La Jolla, CA) [3]. *Wnt11* in situ probe was kindly provided by Andreas Kispert (Hannover Medical School, Hannover, Germany) [21].

Cardiomyocyte Purification

Days 14 and 21 EBs were dissociated with collagenase followed by the digestion with 20 μ g/ml DNase I (Roche, Mannheim, Germany, <http://lifescience.roche.com/shop/en/de/home>). Cells resuspended in ADS buffer (6.8 g/l NaCl, 4.76 g/l HEPES, 0.12 g/l NaH_2PO_4 , 1 g/l glucose, 0.4 g/l KCl, and 0.1 g/l $MgSO_4$) were layered on top of a gradient consisting of a bottom layer of 1.082 g/ml and a top layer of 1.059 g/ml percoll (Sigma-Aldrich) and centrifuged for 30 minutes at 1,851g. Cardiomyocytes from the pellet fraction were subjected to the qRT-PCR analysis. The purity of cardiomyocytes was 80–90% as assessed by immunofluorescence examination (data not shown).

Optical Action Potential Recordings and Analysis

Cardiac explants from 1-month-old EBs were dissociated with collagenase and cardiomyocytes were seeded onto collagen-coated glass coverslips. Cells were measured at days 2 and 3 after dissociation with the voltage sensitive fluorescent probe




Figure 1. Precocious overexpression of Nkx2-5 in mouse ESCs suppresses the cardiac program during early mesoderm development. **(A):** Generation of Nkx2-5OE ESCs by lentiviral-mediated Nkx2-5 overexpression in the *Isl1-nlacZ* knock-in ESC line. An empty IRES-eGFP vector was used to obtain the control GFP ESC line. **(B):** Western blot analysis of Nkx2-5 protein in undifferentiated parental *Isl1-nlacZ* knock-in, GFP, and Nkx2-5OE ESCs. β -Actin is shown as a loading control. **(C):** LacZ reporter gene expression assessed by X-Gal staining in EBs from GFP (top panels) and Nkx2-5OE (bottom panels) ESCs at days (d) 3, 4, and 5 of differentiation. Scale bars = 150 μ m. **(D):** Quantification of β -gal⁺ cells arising during EB differentiation of GFP (black diamonds) and Nkx2-5OE (gray circles) ESCs at indicated time points. Mean values \pm SEM from three experiments; *, $p < .05$ and **, $p < .01$ versus GFP. **(E):** Quantitative reverse transcription polymerase chain reaction analysis of cardiac progenitor genes in GFP (black bars) and Nkx2-5OE (gray bars) differentiating EBs at the indicated time points. Data are mean \pm SEM from three independent experiments; *, $p < .05$ and **, $p < .01$ versus GFP at the same time point. Abbreviations: EB, embryoid body; ESC, embryonic stem cell; FRT, flippase recognition target; GFP, green fluorescent protein; IRES, internal ribosome entry site; PGK, phosphoglycerate kinase; PPT, polypurine tract.

di-8-ANEPPS. Imaging of the dye-labeled cells was performed using a custom-made ultra-fast ratiometric imaging system (image acquisition at 500 frames per second). Recordings were acquired either in Tyrode (basal conditions) or in Tyrode containing 3 or 30 μ M ivabradine. All experiments were performed at 35°C. Details on the optical action potential (AP) recordings and analysis protocol can be found in the Supporting Information Methods.

Statistical Analysis

All data were expressed as means \pm SEM or as weighted means \pm weighted SEM. Data that passed tests for normality and equal variance were analyzed using a two-tailed Student's *t* test. Data that did not fulfill these criteria were subjected to the Mann-Whitney test. Distribution of cardiomyocyte subgroups was analyzed using a Chi-squared test. p values $< .05$ were considered statistically significant.




Figure 2. Constitutive Nkx2-5 and Isl1 overexpression have opposing effects on the specification of Isl1⁺ cardiac progenitors in mouse ESCs. **(A):** Western blot analysis of Isl1 protein in undifferentiated parental *Isl1-nlacZ* knock-in, GFP, and Isl1OE ESCs. β -Actin is shown as a loading control. **(B):** Quantification of β -gal⁺ cells arising during EB differentiation of GFP (black diamonds) and Isl1OE (red squares) ESCs at indicated time points. For better visualization, the number of β -gal⁺ cells per EB is shown at d4 as inset (GFP, black bar; Isl1OE, red bar). Mean values \pm SEM from three experiments; *, $p < .05$ versus GFP. **(C):** Quantitative reverse transcription polymerase chain reaction analysis of cardiac progenitor genes in GFP (black bars) and Isl1OE (red bars) differentiating EBs at the indicated time points. Mean values \pm SEM from three independent experiments; *, $p < .01$ versus GFP at the same time point. **(D):** Quantification of β -gal⁺ cells arising during EB differentiation of GFP (black diamonds), Nkx2-5OE (gray circles), and Isl1OE (red squares) ESCs at indicated time points after mitomycin C (Mit C) treatment at day 3. Mean values \pm SEM from three experiments; *, $p < .05$ versus GFP. **(E):** Representative bright field images of flow cytometry-sorted FDG⁻ (left) and FDG⁺ (right) cells after X-Gal staining; scale bars = 150 μ m. **(F):** Quantitative RT-PCR analysis of *Isl1* transcript in FDG⁻ (black bars) and FDG⁺ (blue bars) cells after flow cytometry purification from GFP, Nkx2-5OE, and Isl1OE 4-day-old EBs. Values are relative to GFP and presented as mean \pm SEM from three independent experiments; *, $p < .01$ versus FDG⁻ cells from the same ESC line. **(G, H):** Flow cytometry analysis for Ki67 (lower panels) and IgG control (upper panels) of FDG⁺ sorted cells from 5-day-old GFP, Nkx2-5OE, and Isl1OE EBs (G). Quantification of Ki67⁺ cells in GFP (black bar), Nkx2-5OE (gray bar), and Isl1OE (red bar) EBs. Mean values \pm SEM from three experiments (H). Abbreviations: EB, embryoid body; ESC, embryonic stem cell; FSC, forward side scatter; GFP, green fluorescent protein.

RESULTS

Precocious Overexpression of Nkx2-5 in Mouse ESCs Suppresses Cardiac and Hemangioblast Programs During Early Mesoderm Development

Using a PGK-IRES-eGFP lentiviral vector system, we constitutively overexpressed Nkx2-5 in the *Isl1-nlacZ* knock-in ESC line (Nkx2-5OE ESCs) in which *Isl1* gene expression can be monitored by expression of β -gal. As control, we generated an analogous line by transfection of the empty PGK-IRES-eGFP vector (GFP ESCs) (Fig. 1A). eGFP expression allowed detection and mechanical isolation of recombinant transduced clones. Overexpression of Nkx2-5 at the protein level was confirmed in undifferentiated Nkx2-5OE ESCs (Fig. 1B). Consistent with our previously reported results [6], *Isl1*-expressing progenitors arose normally within 3–5 days of EB differentiation in control GFP ESCs, as demonstrated by β -gal activity and *Isl1* mRNA transcript detection (Fig. 1C–1E), while *Nkx2-5* just began to be expressed at day 5 (Figs. 1E, 2C). The constitutive precocious overexpression of Nkx2-5 resulted in a delayed appearance and reduction of lacZ positive cells (Fig. 1C, 1D), which was associated with a delayed expression of key transcription factors implicated in SHF progenitor regulation, including *Tbx20* [2], *Gata4* [20], *Fgf10* [22, 23], and *Kdr* [6] (Fig. 1E), suggesting a suppression of *Isl1*-mediated cardiac precursor specification by Nkx2-5. Notably, also *Tbx5*, which is predominantly expressed in FHF precursors [24, 25], and the recently identified FHF progenitor marker *Hcn4* [26, 27], as well as the early cardiac differentiation marker *cTnT* were downregulated in the early stages of EB differentiation of Nkx2-5OE ESCs (Fig. 1E), indicative of a more general inhibition of the cardiac program. These results corroborate the previous findings in global *Nkx2-5* knockout mice, in which lack of Nkx2-5 caused an upregulation and ectopic expression of *Isl1* and other early cardiac progenitor genes, leading to an overspecification of cardiac precursor cells [4]. Because earlier studies suggested that hematopoietic and endothelial cells as well as cardiomyocytes and endothelial/smooth muscle cells are derived from common progenitors expressing *Kdr* [28, 29] and this gene was upregulated in Nkx2-5OE EBs at day 5, we also examined whether forced overexpression of Nkx2-5 during early ESC differentiation could change the commitment of mesodermal progenitors from the cardiac toward the hemangioblast fate. Quantitative RT-PCR analysis for different endothelial/hematopoietic markers (*Cd34*, *Pecam-1*, *Cdh5*, *Tie2*, and *Gata1*) as well as the smooth muscle gene *Acta2* revealed that all these transcripts were downregulated in 5-day-old Nkx2-5OE EBs (Supporting Information Fig. S1), suggesting that the cardiac regulator Nkx2-5 acts also as repressor of the hemangioblast program during mouse mesoderm fate determination in vitro, similarly to its reported effects in vivo [30, 31].

Nkx2-5 Negatively Regulates Cardiac Progenitor Specification by Direct Inhibition of *Isl1* Transcription

We further tested the hypothesis that the negative effects of Nkx2-5 on cardiac progenitor development of mouse ESCs in vitro are caused by repression of *Isl1* and its transcriptional program. We first generated an *Isl1-nlacZ* knock-in ESC line that overexpresses *Isl1* (*Isl1OE* ESCs) (Fig. 2A) and analyzed whether constitutive *Isl1* overexpression would have opposite effects on the initiation of the cardiac program as compared

to those exerted by Nkx2-5. Indeed, β -gal activity and expression profiling revealed an increased number of lacZ positive cells arising at day 4 of EB differentiation and a consistent upregulation of SHF and FHF cardiac progenitor markers in *Isl1OE* compared to control GFP ESCs (Fig. 2B, 2C), indicating opposed regulation of cardiac induction by the two transcription factors. To dissect the specific contribution of cell specification and proliferation to the observed phenotypes, we first compared the occurrence of lacZ positive cells during early EB differentiation of the control GFP, *Isl1OE*, and Nkx2-5OE lines in presence of the antimetabolic agent mitomycin C (Fig. 2D). Mitomycin C treatment of 3-day-old EBs resulted in a striking reduction of lacZ positive cells arising at days 4 and 5 of EB differentiation in both GFP and *Isl1OE* ESCs (Fig. 2D). No cells expressing β -gal were detected in the Nkx2-5OE line after mitomycin C application (Fig. 2D), indicating a lack of *Isl1*⁺ progenitor specification during early stages of Nkx2-5OE EBs. Moreover, the number of lacZ positive cells specifying at 4-day-old EBs was significantly higher in the *Isl1OE* condition compared to control and did not progressively increase at day 5 (Fig. 2D), indicating that induction of *Isl1*⁺ progenitors is indeed increased and faster completed in the *Isl1OE* line. We further examined the proliferation capacity of purified *Isl1*⁺ cardiac progenitors from 5-day-old EBs of Nkx2-5OE, *Isl1OE*, and GFP ESCs. Isolation of *Isl1*⁺/lacZ⁺ cells was performed by fluorescence-activated cell sorting (FACS) after labeling with the fluorogenic, lipophilic β -gal substrate C₁₂FDG (Supporting Information Fig. S2), as previously described [32]. Subsequent X-Gal staining on a small fraction of sorted cells demonstrated a purity of 90–95% of the C₁₂FDG⁺ cells (Fig. 2E), and *Isl1* expression was significantly increased in C₁₂FDG⁺ cells compared to C₁₂FDG⁻ cells, as measured by qRT-PCR (Fig. 2F). Immunostaining for the proliferation marker Ki67 revealed similar proliferation rates of purified *Isl1*⁺/lacZ⁺ progenitors from the different transgenic ESC lines, with a tendency to a slightly higher proliferation in *Isl1OE* cells (Fig. 2G, 2H). These findings suggest that the differences in the number of lacZ⁺ cells observed upon constitutive *Isl1* and Nkx2-5 overexpression mainly arise from opposing effects on *Isl1*⁺ progenitor specification by the two transcription factors. Moreover, overexpression of *Isl1* in Nkx2-5OE ESCs compensated for Nkx2-5 repressive effects in this context (Supporting Information Fig. S3), further supporting a possible role of *Isl1* as target for Nkx2-5 action.

We next performed ChIP analysis on day 4 differentiating EBs from the *Isl1-nlacZ* knock-in ESC line in order to identify direct *Isl1* target genes. We selected several of the identified genes with potential roles in regulating *Isl1* progenitor biology and whose ablation in mouse leads to cardiac phenotypes, and further analyzed their expression in the *Isl1OE* and Nkx2-5OE ESCs. These genes belong to signaling pathways involved in cardiac development, such as the bone morphogenetic protein receptor, type 1B (*Bmpr1b*), the Notch ligand delta-like 1 homolog (*Dlk1*) and the WNT inhibitory factor 1 (*Wif1*), or regulate cell growth and differentiation (the ret proto-oncogene, *Ret*), migration (the transmembrane protein *Odz1* and the axon guidance receptor *Robo2*) and transcription (the myocardial SNF1-like kinase, *Snf1lk*), or are either cardiac transcription factors (the SRY-box containing gene 6, *Sox6*), cardiac progenitor markers (the insulin-like growth factor binding protein 5, *Igfbp5*), or cardiac muscle genes (the cardiac troponin




Figure 3. Nkx2-5 negatively regulates cardiac progenitor specification by direct inhibition of *Isl1* transcription. **(A):** Expression levels of *Isl1* downstream target genes in FDG^+ cells sorted from GFP (black bars), Nkx2-5OE (gray bars), and *Isl1*OE (red bars) 4-day-old embryoid bodies (EBs). Values are relative to GFP and presented as mean \pm SEM from three independent experiments; *, $p < .05$ and **, $p < .01$ versus GFP. **(B):** Genomic locus of *Isl1* gene 10 kb upstream and 10 kb downstream of the coding sequence with predicted Nkx2-5 binding sites (5'-TYAAGTG-3'). The 3.9-kb region at 4.3 kb upstream of the *Isl1*-ATG contains three highly conserved Nkx2-5 binding sites, as shown in a cross-species sequence comparison. **(C):** Bar graph of luciferase activity. A minimal-promoter-containing pgl4.24 vector is compared with the same vector containing the 3.9 kb DNA piece upstream of *Isl1* highlighted in panel B. Experiments are performed in C3H 10T1/2 cells after cotransfection with an empty expression vector (basal) or with vectors encoding Nkx2-5 and GFP. Data are means \pm SEM; **, $p < .01$; $n = 8$. **(D):** Electromobility shift assay using 27–29 bp labeled probes containing each Nkx2-5 binding site within the 3.9 kb region upstream of *Isl1*. A black arrow indicates the shifted band. Nuclear extract of HEK293T cells overexpressing Nkx2-5 is used to induce shifting. :10, nuclear extract diluted 1 to 10. Nonlabeled oligos and mutated nonlabeled oligos are used as competitors. Mutated, labeled oligos are used as negative control. Abbreviations: GFP, green fluorescent protein; RLU, relative light unit.

T, *Tnnt2*, and the myocyte-enriched calcineurin-interacting protein 1, *Dscr111*). For all selected genes, specific enrichment in the precipitated DNA could be validated by quantitative PCR analysis (Supporting Information Fig. S4).

In order to test whether the delay of cardiac progenitor specification in Nkx2-5OE ESC-derived cells was mediated by an inhibition of *Isl1* transcription, we analyzed the expression level of *Isl1* and its selected downstream target genes in

FACS-sorted $C_{12}FDG^+/Isl1^+$ cardiac progenitors from day 5 differentiating EBs of Nkx2-5OE, *Isl1*OE, and GFP ESCs. Quantitative RT-PCR analysis demonstrated a nearly 50% reduction of *Isl1* transcripts in Nkx2-5-overexpressing cells, which was accompanied by a dysregulation of *Isl1* target genes (Fig. 3A). Importantly, the changes in expression levels of all selected *Isl1* target genes occurred in opposite direction compared to those induced by *Isl1*, strongly suggesting that Nkx2-5 is a




Figure 4. Negative regulation of *Isl1* by *Nkx2-5* occurs during second heart field progenitor differentiation into cardiomyocytes in vivo. **(A):** *Isl1*-Cre knock-in mice (*Isl1*^{Cre/+}) were crossed with mice carrying floxed *Nkx2-5* alleles (*Nkx2-5*^{fl/fl}) to generate tissue-specific deletion of *Nkx2-5*. **(B):** Whole-mount in situ analysis for expression of *Nkx2-5* mRNA (dark blue) in *Isl1*-Cre;*Nkx2-5* mutants (*Isl1*^{Cre/+}; *Nkx2-5*^{fl/fl}, right panels) and somite-matched littermate controls (*Isl1*^{+/+}; *Nkx2-5*^{fl/fl}, left panels) at ED9.5 (20–21 somite pairs). **(C):** Whole-mount RNA in situ hybridization for *Isl1* in ED9.0 embryos (16 somite pairs) from *Isl1*^{+/+}; *Nkx2-5*^{fl/fl} controls (left panels) and *Isl1*^{Cre/+}; *Nkx2-5*^{fl/fl} mutants (right panels). Arrows indicate persisting *Isl1* expression in the forming ventricular and atrial regions of the mutant hearts. Images are representative of five embryos per genotype. **(D):** Representative images of transverse sections of control *Isl1*^{+/+}; *Nkx2-5*^{fl/fl} (left panels) and mutant *Isl1*^{Cre/+}; *Nkx2-5*^{fl/fl} (right panels) ED9.25 embryos (18–19 somite pairs) after immunofluorescence analysis of *Isl1* (red) and cTnT (green) protein expression. Sections correspond to the position indicated by the lines drawn through the adjacent embryo view. Scale bars = 50 μ m. Images are representative of three embryos per genotype. White bracket marks malformed RV/OFT in *Nkx2-5* mutants. Abbreviations: A, atria; AVC, atrioventricular canal; LA, left atrium; LV, left ventricle; OFT, outflow tract; RV, right ventricle; SV, sinus venosus; V, ventricle.

negative regulator of *Isl1* transcription. This hypothesis was also corroborated by a lower C₁₂FDG fluorescence (Supporting Information Fig. S2B) and X-Gal staining intensity (Fig. 1C) of *Isl1*⁺/*lacZ*⁺ cells derived from *Nkx2-5*OE ESCs compared to control GFP ESCs.

To determine whether *Nkx2-5* can directly repress *Isl1* transcription, we analyzed evolutionarily conserved regions within ± 10 kilobase (kb) of the transcription start site (TSS) of the *Isl1* gene for the presence of *Nkx2-5* DNA-binding sites. A cluster of three putative *Nkx2-5* DNA-binding motifs (5'-TYAAGTG-3') was found in the region 4.5–8.0 kb upstream of the TSS (Fig. 3B). We examined the ability of the -4.5 to -8.0 kb *Isl1* enhancer region to regulate transactivation of a luciferase reporter construct by *Nkx2-5*. Introduction of the -4.5 to -8.0 kb *Isl1* enhancer element upstream of a minimal promoter resulted in an about threefold increase in basal luciferase activity compared to the empty vector (Fig. 3C). However, this increase was completely abolished by *Nkx2-5*,

while no effect was observed with a control protein (GFP) (Fig. 3C), suggesting that *Nkx2-5* acts as a transcriptional repressor at the in silico identified *Nkx2-5* affinity sites. To determine whether the candidate *Nkx2-5* sites in the -4.5 to -8.0 kb *Isl1* enhancer region might represent bona fide cis-acting elements, we tested each of the three sites for *Nkx2-5* binding by EMSAs. *Nkx2-5* specifically bound to all three sites, since the binding was efficiently competed by excess of unlabeled probes, but not by mutant versions of unlabeled competitors, and was abolished using mutated labeled probes (Fig. 3D).

Negative Regulation of *Isl1* by *Nkx2-5* Occurs During SHF Progenitor Differentiation into Cardiomyocytes In Vivo

To further investigate the biological significance of *Isl1* inhibition by *Nkx2-5* in vivo, we performed Cre-mediated excision of *Nkx2-5* in the *Isl1* lineage. We crossed mice that were

floxed for *Nkx2-5* (*Nkx2-5^{fl/fl}*) [11] to *Isl1^{Cre/+}* mice, in which the Cre recombinase is expressed under control of the *Isl1* locus [12] (Fig. 4A). *Isl1^{Cre/+};Nkx2-5^{fl/fl}* mice exhibited growth retardation at around ED9.0 and died at around ED10.5, consistently with recently reported data [33]. Whole-mount RNA ISH showed that the *Isl1*-Cre-mediated recombination of floxed *Nkx2-5* alleles was efficient and tissue specific (Fig. 4B and Supporting Information Fig. S5A, S5B). Interestingly, *Nkx2-5* transcript was lost in almost all cells forming the heart of *Isl1^{Cre/+};Nkx2-5^{fl/fl}* mice at ED9.5 (Fig. 4B), demonstrating that *Isl1* is indeed a pan-cardiac progenitor cell marker, as previously suggested [5]. Morphological comparison of *Isl1^{+/+};Nkx2-5^{fl/fl}* littermates to their mutant counterparts at ED9–9.5 (16–21 somite pairs) (Fig. 4B, 4C) indicated a grossly truncated outflow tract (OFT) and indistinct right ventricle (RV), with forward growth of the ventricle in the absence of looping morphogenesis, thus highlighting a prominent SHF defect, similar to that observed in global *Nkx2-5* null mice [4, 8]. Loss of RV and foreshortened OFT in *Isl1^{Cre/+};Nkx2-5^{fl/fl}* mutants was also confirmed by ISH analysis using markers for OFT and ventricular tissue identity (Supporting Information Fig. S6). Importantly in *Isl1^{Cre/+};Nkx2-5^{fl/fl}* mutants at ED9.0 *Isl1* transcript was rather decreased in SHF progenitor cells that were added to the arterial and venous poles, but persisted in cardiomyocytes of the heart tube (Fig. 4C, 4D and Supporting Information Fig. S5C–S5F). A detailed examination of *Isl1* expression by immunohistochemistry confirmed that *Isl1* protein was still maintained throughout the whole mutant heart (Fig. 4D), while in the control littermates *Isl1* was only detectable in the differentiating myocytes of the OFT and nascent myocardium of the sinus venosus, the primitive pacemaker region that later gives rise to the sinoatrial node. Furthermore, the number of *Isl1* positive cells in the splanchnic mesoderm and foregut endoderm as well as their proliferative index scored by phosphohistone H3 did not significantly differ in *Isl1^{Cre/+};Nkx2-5^{fl/fl}* mutants (Supporting Information Fig. S7), suggesting that the lower *Isl1* transcript signal observed by ISH in SHF progenitors is likely to be attributable to the 50% reduction of *Isl1* expression in heterozygous *Isl1^{Cre/+}* mice (Supporting Information Fig. S8) rather than to a defect in proliferation.

Together, these results suggest that inhibition of *Isl1* transcription by *Nkx2-5* is likely to occur in vivo during SHF progenitor differentiation and identify *Nkx2-5* as direct responsible mediator of *Isl1* repression in differentiated cardiomyocytes of the working myocardium.

Overexpression of *Isl1* Does Not Prevent Cardiac Differentiation in Mouse ESCs and *Xenopus laevis* Embryos

In order to investigate the functional role of *Nkx2-5*-mediated repression of *Isl1* during cardiac differentiation, we first analyzed the in vitro cardiac differentiation potential of *Isl1*OE ESCs (Fig. 5A–5E). Interestingly, overexpression of *Isl1* did not prevent these cells from generating functional cardiomyocytes, as demonstrated by the appearance of a contractile phenotype in differentiating cultures (Fig. 5A). To the contrary, cardiac differentiation as measured by the appearance of spontaneously beating foci occurred significantly earlier in comparison to GFP (Fig. 5A and Supporting Information Fig. S9A). Marker gene analyses by semiquantitative RT-PCR

indicated a continuous and strong expression of exogenous *Isl1* in days 6–14 EBs from the *Isl1*OE line and upregulation of genes linked to SHF development, for example, *Bmp4*, *Foxc2*, or *Fgf8* (Supporting Information Fig. S9B). In concordance with the increased number in contractile areas, immunofluorescence revealed more and larger areas of cells positive for the cardiac specific sarcomeric protein Troponin T (cTnT) in *Isl1*OE when compared to GFP EBs (Fig. 5B). Flow cytometry analysis confirmed that constitutive *Isl1* overexpression led to a ~6-fold increase in differentiated cardiomyocytes (Fig. 5C), likely due to the enhanced specification of cardiac progenitors (Fig. 2B, 2C). A closer inspection of differentiated single cardiomyocytes demonstrated the formation of a normal contractile apparatus in *Isl1*-overexpressing cells, as shown by immunostaining for the Z-disk protein α -actinin and the A-band protein cTnT (Fig. 5D and Supporting Information Fig. S10). In both cases, a clear sarcomeric patterning similar to the control situation was observed (Supporting Information Fig. S10). Interestingly, when comparing the beating frequency of contracting areas of differentiating EBs, we found that *Isl1*-overexpressing cells exhibited a faster spontaneous firing rate than GFP (Fig. 5E and Supporting Information Fig. S9C), which is typical of nodal myocytes [34]. This finding is in accordance with the upregulation of the pacemaker ion channel gene *Hcn4* as demonstrated by RT-PCR in differentiating *Isl1*OE EBs (Fig. 2C and Supporting Information Fig. S9B).

To further substantiate these findings in vivo, we performed *Isl1*-gain-of-function experiments in *Xenopus laevis* embryos. As we showed previously, *Xenopus isl1* and *nkx2-5* are coexpressed in the common cardiac progenitors. Whereas *isl1* expression in cardiac cells is downregulated, *nkx2-5* expression persists during differentiation of cardiomyocytes also in *X. laevis* [14, 15]. We microinjected RNA coding for *Xenopus isl1* into the presumptive cardiac region of *Xenopus* embryos at eight-cell stage. GFP RNA was coinjected to select for correctly injected embryos that harbor GFP expression in the cardiogenic region (Fig. 5F). To monitor cardiac induction and differentiation, we analyzed the expression of the early cardiac markers *nkx2-5*, *tbx20*, and *mef2d* at stage 20 (Fig. 5G, 5H) as well as cardiac *tnni3*, *myh6*, and *tbx5* at stage 28 (Fig. 5I, 5J), and did not observe any changes. However, *tnnt2*, *igfbp5*, and *mef2c*, which were identified as *Isl1* downstream target genes in our ChIP analysis of differentiating mouse ESCs, were upregulated in *Isl1*-overexpressing hearts at stage 24, as measured by semiquantitative RT-PCR (Fig. 5K). Moreover, the beating frequency of the developing heart in *Xenopus* embryos at stage 42 was faster upon *Isl1* overexpression (Fig. 5L). Taken together, these observations support our finding in murine ESCs that *Isl1* gain of function does not interfere with differentiation of cardiac progenitors toward cardiomyocytes but rather may influence SAN versus working myocardial cell fate.

Isl1 Regulates Expression of Cardiac Subtype-Specific Genes

We used qRT-PCR to compare the expression of a panel of subtype-specific genes in control GFP and *Isl1*OE ESC-derived cardiomyocytes at different maturation stages. Interestingly, many genes important for development and function of SAN cells were significantly upregulated in *Isl1*OE cardiomyocytes (Fig. 6A). These included members of the hyperpolarization-activated cyclic nucleotide-gated channel family, *Hcn4* and

Hcn1 [35, 36], several components of T- and L-type voltage-dependent Ca^{2+} channels, such as the α -subunits Cav3.1 (*Cacna1g*) and Cav1.2 (*Cacna1c*) as well as the auxiliary subunit Cav α 2 δ 2 (*Cacna2d2*) [37, 38], and critical transcriptional regulators of SAN formation, such as the T-box transcription factor *Tbx2* [39, 40] (Fig. 6A). In contrast, expression of *Irx4* and *Hey2* transcription factors, which play a crucial role in

establishing ventricular chamber specification of the developing heart [41–44], was reduced in Isl1OE cardiomyocytes (Fig. 6A). In addition, these cells failed to upregulate the ventricular specific isoform of myosin light chain 2 (*Myl2*) [45, 46] and other genes essential for working-myocardium identity and function, such as the α -subunit of the cardiac sodium channel Nav1.5 (*Scn5a*) [35] and the high




Figure 5.

conductance connexin 43 (*Gja1*) [47] (Fig. 6A). Likewise, the gap junction protein Cx40 (*Gja5*) and the atrial chamber specification factor Anf (*Nppa*), both early and specific markers of the working-type cardiomyocytes in the nascent atrial and ventricular chambers [47–50], were downregulated in Isl1OE cardiomyocytes (Fig. 6A). Interestingly, expression of the atrial specific isoform of the myosin light chain 2 (*MyI7*), which is detected throughout the whole early developing mouse heart and becomes predominant in the atrial tissue and SAN at later embryonic stages [51], was rather increased in Isl1OE cardiomyocytes (Fig. 6A). These data further suggested that maintained Isl1 expression in differentiating cardiomyocytes might negatively affect their working-myocardium fate in favor of a nodal phenotype.

To investigate whether the alterations in gene expression profile in the Isl1OE cardiomyocytes indeed reflect a different relative abundance of cardiac cell subtypes, we first performed coimmunofluorescence analysis in 1-month-old dissociated cardiomyocytes using antibodies specific for the ventricular and atrial isoforms of the myosin light chain sarcomeric protein (Mlc2v and Mlc2a) as well as the Hcn4 channel, which is highly expressed in the SAN and is required for mature cardiac pacemaker activity [52] (Fig. 6B–6E). In the control GFP group, we detected a similar percentage of cells uniquely expressing Mlc2v ($43\% \pm 3\%$) or Mlc2a ($40\% \pm 4\%$) in a well-organized, striated pattern; a minority ($17\% \pm 2\%$) was positive for both isoforms, likely representing cardiomyocytes in the stage of specification into the ventricular lineage (Fig. 6C). Interestingly, costaining for the Mlc2 proteins and the Hcn4 pacemaker channel revealed that $14\% \pm 2\%$ of the Mlc2a positive cardiomyocytes also expressed Hcn4, while no cells only Hcn4⁺ or Mlc2v⁺/Hcn4⁺ were found (Fig. 6D, 6E). The same quantitative analysis in cardiomyocytes differentiated from the Isl1OE line demonstrated a significant, striking reduction of Mlc2v positive cells ($6\% \pm 1\%$ Mlc2v⁺ and $6\% \pm 1\%$ Mlc2v⁺/Mlc2a⁺) in favor of Mlc2a expressing cells ($88\% \pm 2\%$), with more than a third of the latter costaining positively for Hcn4 ($38\% \pm 2\%$) (Fig. 6C, 6E).

These protein analysis results are consistent with the transcript levels measured by qRT-PCR, and all together suggest a possible function of Isl1 in controlling myocardial cell fate by repressing the ventricular gene program and promoting specification into the nodal lineage.

Isl1 Represses Specification of the Ventricular Lineage While Promoting Sinoatrial Node Fate

We further confirmed the hypothesis that Isl1 regulates cell subtype identity during cardiomyocyte differentiation by analyzing the electrophysiological properties of 1-month-old, spontaneously beating single cells isolated from the Isl1OE and control GFP ESC lines. We performed optical imaging of APs [53, 54], which has been recently demonstrated to allow rapid and robust phenotyping of large numbers of pluripotent stem cell-derived cardiomyocytes [55, 56]. Action potentials serve as a “finger-print” of different cardiomyocyte lineages. Atrial- and ventricular-like APs differ in their plateau shape and duration at 50% (APD50) and 90% (APD90) of repolarization, with the ventricular one having a longer plateau and the atrial being more triangular [57]. Thus, we could distinguish these two types of APs based on the value of the ADP90/APD50 ratio [58], which ranged between 1.2 and 1.9 for the ventricular and was larger than 2.5 for the atrial phenotype, respectively (Fig. 7A). The identification of nodal-like APs was based on the prominent diastolic depolarization (DD) phase (Fig. 7A) and on their sensitivity to ivabradine, a specific and selective blocker of the cardiac pacemaker “funny” current (*I_f*) generated by the Hcn channels [59]. Consistently with previous studies on murine embryonic cardiomyocytes [60], treatment with 30 μM ivabradine—a concentration that is sufficient to achieve a complete *I_f* block [61]—was able to abolish the spontaneous activity selectively in the nodal cells, while only a reduction of frequency was observed for the APs with a ventricular-like or atrial-like phenotype (Supporting Information Fig. S11). Similar findings have been recently reported in mouse ESC-derived cardiomyocytes using ZENECA ZD7288 as specific Hcn channel blocker [62]. Based on the unique AP traits and the

Figure 5. Constitutive overexpression of Isl1 does not prevent cardiac differentiation in mouse embryonic stem cells (ESCs) and in *Xenopus laevis* embryos. **(A):** Analysis of beating activity during EB differentiation of GFP (top) and Isl1OE (bottom) ESCs. Median values, first and third quartile as well as minimal and maximal values are given of five independent experiments; *, $p < .005$ versus GFP ESC line. **(B):** Representative images of 14-day-old EBs from GFP and Isl1OE ESCs after immunofluorescence staining for cTnT (red), indicating that Isl1 overexpression results in bigger myocyte clusters; scale bars = 100 μm. **(C):** Flow cytometry-based quantification of cTnT⁺ cells at 14 days of EB differentiation of GFP and Isl1OE ESCs. Mean values ± SEM from eight independent experiments. **(D):** Immunofluorescence images of GFP and Isl1OE cardiomyocytes following staining with antibodies against Isl1 (red) and cTnT (green); nuclei (blue) are visualized by DAPI. Scale bars = 15 μm. **(E):** Beating frequency of contractile areas in GFP (black filled squares) and Isl1OE (black filled triangles) EBs at 14 days of differentiation. Mean values ± SEM, $n = 170$ for GFP and $n = 150$ for Isl1OE from six to seven independent experiments. **(F):** GFP expression after unilateral and bilateral coinjection of GFP and *Isl1* mRNA into the cardiac region of *Xenopus* embryos. The cement gland is indicated by dashed white circles. **(G, H):** Whole-mount RNA in situ analysis of *Xenopus* embryos for expression of the cardiac markers *nkx2-5*, *tbx20*, and *mef2d* (blue) after unilateral injection of GFP alone (upper images) or in conjunction with *isl1* (lower images) in the forming hearts of stage 20 *Xenopus* embryos. The cement gland is indicated by dashed white circles (G). Percentage of embryos with normal expression of the tested marker genes on the injected side compared to the uninjected side is indicated in the bar graph; $n = 53$ –85 for GFP (black bars) alone and $n = 67$ –88 for *isl1* (red bars) from three to four independent experiments (H). **(I, J):** Whole-mount RNA in situ of *Xenopus* embryos analysis for expression of the cardiac markers *tnni3*, *myh6*, and *tbx5* (blue) after unilateral injection of GFP alone (upper images) or in conjunction with *isl1* (lower images) in the forming hearts of stage 28 *Xenopus* embryos. The cement gland is indicated by dashed white circles (I). Percentage of embryos with normal expression of the tested marker genes on the injected side compared to the uninjected side is indicated in the bar graph; $n = 63$ –111 for GFP (black bars) alone and $n = 61$ –78 for *isl1* (red bars) from three to four independent experiments (J). **(K):** RT-PCR expression analysis of Isl1 downstream target genes after bilateral injection of GFP alone or in conjunction with *isl1* on heart explants of stage 24 *Xenopus* embryos. Changes in gene expression were observed in at least three out of four independent experiments. **(L):** Beating frequency of *Xenopus* hearts after bilateral injection of GFP mRNA alone (black filled circles) and GFP/*isl1* mRNAs (black filled squares) at stage 42. Mean values ± SEM, $n = 60$ for GFP alone and $n = 80$ for GFP/*isl1* from three independent experiments. Abbreviations: EB, embryoid body; GFP, green fluorescent protein; mRNA, messenger RNA.




Figure 6. Overexpression of *Isl1* promotes expression of nodal lineage markers and represses ventricular program of differentiating myocytes. **(A):** Expression level of genes specific for nodal and working-myocardium lineages was determined by qRT-PCR in GFP and *Isl1OE* cardiomyocytes at days 14 and 21 in independent EB differentiation experiments (as indicated by numbers). All values are normalized to *Gapdh* and are relative to the average expression value measured in GFP cells from differentiations 1 and 2 at day 14. *p* values were calculated using the Mann-Whitney test. Minimum (min) and maximum (max) values were taken as a reference for heatmap representation. **(B, C):** Immunofluorescence analysis of Mlc2a (green), Mlc2v (magenta), and F-actin (red, visualized with Phalloidin) in 1-month-old GFP and *Isl1OE* cardiomyocytes. Scale bars = 25 μ m (B). Quantification of Mlc2a⁺, Mlc2v⁺ and Mlc2a/Mlc2v-double positive myocytes from GFP (top) and *Isl1OE* ESCs (bottom). Mean values \pm SEM, *n* = 189 for GFP and *n* = 535 for *Isl1OE* from five to six independent experiments (C). **(D, E):** Immunofluorescence analysis of Mlc2a (green), *Hcn4* (magenta), and F-actin (red, visualized with Phalloidin) in 1-month-old GFP and *Isl1OE* cardiomyocytes. Scale bars = 25 μ m (D). Quantification of *Hcn4*⁺ cells in the Mlc2a⁺ myocyte fraction from GFP and *Isl1OE* ESCs. Mean values \pm SEM, *n* = 86 for GFP and *n* = 83 for *Isl1OE* from two to three independent experiments. Abbreviation: GFP, green fluorescent protein.




Figure 7. *Isl1* overexpression affects subtype diversification of electrophysiologically functional cardiomyocytes. **(A):** Representative action potential (AP) traces and corresponding APD₉₀/APD₅₀ ratios (R) of 1-month-old ventricular-, atrial-, nodal-like, and intermediate cardiomyocytes from GFP and *Isl1*OE ESCs, as determined with optical imaging using di8-ANEPPS. **(B):** Quantification of 1-month-old ventricular-, atrial-, nodal-like, and intermediate cardiomyocytes from GFP and *Isl1*OE ESCs based on the unique AP traits and the pharmacological response to ivabradine. Mean values ± SEM, *n* = 122 for GFP and *n* = 65 for *Isl1*OE from three independent experiments. **(C):** Percentage of reduction of early and total DD slope as well as AP frequency in 1-month-old nodal cardiomyocytes from GFP (black bars) and *Isl1*OE (red bars) ESCs after 3 μM *Iva* application. **(D):** Working model for the regulation of cardiomyocyte subtype specification by *Isl1*/*Nkx2-5*-mediated mechanism. Abbreviations: DD, diastolic depolarization; GFP, green fluorescent protein; *Iva*, ivabradine.

pharmacological response to ivabradine, we found that the cardiomyocyte population arising from the control GFP ESC line consisted of 53% ± 2% ventricular, 7% ± 2% atrial, 20% ± 5% nodal, and 20% ± 5% "intermediate" cells, with an AP shape in between the ventricular and atrial phenotype (Fig. 7B). These findings are in accordance with previously published results obtained with classical patch-clamp electrophysiology [63]. Importantly, only 14% ± 3% of the cardiomyocytes overexpressing *Isl1* showed ventricular-like APs, while no change in the proportion of the atrial-like (11% ± 2%) and "intermediate" (20% ± 6%) AP traits was observed (Fig. 7B). Moreover, 30 μM ivabradine completely abolished the spontaneous electrical firing in more than half of the *Isl1*OE cells (55% ± 7%), all of which presented marked diastolic depolarization, confirming their nodal identity (Fig. 7B). These results suggested that *Isl1* expression in differentiating cardiomyocytes results in an increased specification of the nodal lineage at the expense of the ventricular population. To further investigate whether this effect might associate with an *Isl1*-dependent upregulation of Hcn channels during cardiomyocyte induction, we compared the amount of *I_f* current in control GFP and *Isl1*OE cells with a nodal-like phenotype by measuring the changes in the steepness of the DD and spontaneous beating rate induced by 3 μM ivabradine, a concentration that blocks only ~ 60% of *I_f* current in SAN cells [64]. We did not observe any significant

differences in both parameters between the two groups (Fig. 7C), suggesting a similar expression of Hcn channels in the nodal cells.

DISCUSSION

Despite the tremendous progress made during the last 20 years in understanding the molecular mechanisms that govern cardiomyocyte diversification, several questions remain concerning the fine-tuning of the expression of key developmental regulators, their exact contribution to cardiomyocyte specification and their interaction. During cardiogenesis, *Isl1* and *Nkx2-5* are coexpressed in cardiac progenitors of the SHF and are essential for their proper development [3, 4, 6]. Subsequently, *Isl1* is downregulated in the differentiating myocytic progeny, while *Nkx2-5* expression is maintained and even increases in these cells [6]. Several activators of *Isl1* expression have been identified, including *Tbx1*, *Fgf8*, *Shox2*, Forkhead proteins, *Gata4*, and *Oct1* [65–70]. In contrast, little is known about factors that negatively regulate *Isl1* and its transcriptional program. In this context, direct repression of *Isl1* transcription in the developing heart has been ascribed to *Tbx20* [71]. However, since upregulation of *Isl1* does not account for the cardiac defects observed in *Tbx20* null mice [71], the biological significance of this regulation still needs to be explored. Recently,

analysis of the developing heart of global *Nkx2-5* knockout mice and zebrafish embryos revealed upregulation of *Isl1* and other progenitor markers of the SHF and their ectopic expression in differentiating myocytes, suggesting a major role for *Nkx2-5* in modulating expression of genes associated with cardiac induction and progenitor cell status [4, 18]. Our data indicate that *Nkx2-5* can directly regulate *Isl1* transcription and is responsible for its downregulation in differentiating myocytes of the working ventricular myocardium (Fig. 7D).

Nkx2-5 Is a Direct Regulator of Isl1 Expression

Our results led us to the conclusion that the transcription factor *Nkx2-5* directly represses *Isl1* expression, thereby controlling its transcriptional program: (a) constitutive overexpression of *Nkx2-5* led to downregulation of *Isl1* and its downstream targets in differentiating murine *Isl1-nLacZ* knock-in ESCs; (b) conditional knockout of *Nkx2-5* in the *Isl1* lineage resulted in persistent expression of *Isl1* in the developing heart tube, corroborating the findings in global *Nkx2-5* deficient mice [4]; and (c) we identified a conserved -4.5 to -8.0 kb region within the *Isl1* enhancer that contained three consensus *Nkx2-5* binding sites and demonstrated direct binding and regulation by *Nkx2-5*. Interestingly, recent molecular and genetic analysis of a *Fgf10* cardiac element indicated that *Isl1* and *Nkx2-5* can have overlapping binding sites for which they compete, making target gene expression dependent on the expression ratio of these two transcription factors [72]. Thus, a similar regulatory relationship between *Isl1* and *Nkx2-5* may also be valid for the identified *Isl1* downstream targets that showed opposite regulation in *Isl1*⁺ progenitors overexpressing either *Nkx2-5* or *Isl1*.

Furthermore, we showed that forced overexpression of *Nkx2-5* in differentiating mouse ESCs leads to inhibition of cardiac specification, confirming studies attributing a negative regulation of cardiovascular progenitor genes to *Nkx2-5* [4]. Intriguingly, previous constitutive overexpression of the human *NKX2-5* transcript in mouse ESCs through the cytomegalovirus (CMV) promoter has been reported to enhance cardiogenesis in vitro, leading to preferentially differentiated ventricular cardiomyocytes [63]. Since specification and differentiation of cardiac lineages during embryonic development is under tight spatial and temporal control that is achieved by the fine regulation of gene networks [1, 2, 73], these discrepancies are likely attributable to technical variances that might result in temporal and cell type differences of *Nkx2-5* dosage during ESC differentiation. For instance, compared to the CMV promoter, whose effectiveness is very cell-lineage dependent, the phosphoglycerate kinase-1 (PGK) promoter used in our transgenic lines drives a higher and more stable transgene expression in undifferentiated ESCs and is strongly active in almost all mouse ESC derivatives [74]. In contrast to *Nkx2-5* overexpression, forced *Isl1* expression promoted *Isl1*⁺ precursors and positively regulated cardiac progenitor markers, substantiating earlier work on *Isl1* knockout mutant. Importantly, *Isl1* could rescue the cardiac specification defect caused by *Nkx2-5*, indicating that this phenotype was likely driven by a downregulation of the *Isl1* program, which is necessary for early cardiac progenitor specification [3].

In addition, we provide further evidence that *Isl1* is likely to be a pan-cardiac progenitor marker [4, 5, 14, 75, 76]. First, *Isl1* activated genes of both FHF and SHF during cardiac differentiation of *Isl1OE* ESCs. Second, conditional ablation of *Nkx2-5*

specifically in the *Isl1* expression domain resulted in the absence of *Nkx2-5* in virtually all cells of the heart and not only in the SHF derivatives, placing *Isl1* high in the hierarchy of the transcription factors active in cardiac progenitors [75].

Isl1 Coordinates Cardiomyocyte Subtype Specification by Repressing the Ventricular Lineage and Promoting the Sinoatrial Node Fate

In ED8.25 mouse embryos, *Isl1*⁺ progenitor cells are found dorsal of the developing heart tube in the mesenchyme adjacent to the foregut endoderm. When these cells migrate into the developing heart, they lose *Isl1* expression and increase *Nkx2-5* levels [6]. Our results suggest that *Nkx2-5* may be directly responsible for the downregulation of *Isl1* expression in cardiomyocytes and its confinement to the cardiac precursors. Previous work by others has shown that transient overexpression of *Isl1* during EB differentiation leads to an expansion of the myocytic fraction [77, 78]. However, the consequences of sustained *Isl1* expression and, thus, the biological significance of *Isl1* repression in cardiomyocytes were not explored until now. Our study revealed that constitutive *Isl1* expression during cardiac development in vitro and in vivo does not prevent myocytic differentiation. On the contrary, we show that excess of *Isl1* results in an increased number of myocytes. In addition, our molecular expression profiling combined with the functional analysis of action potentials demonstrated that failed downregulation of *Isl1* during cardiac differentiation of mESCs controls cardiomyocyte lineage diversification by repressing the ventricular and promoting the sinoatrial node fates.

Immature cardiomyocytes derived from the in vitro-differentiated ESCs display properties of nodal cells, making it difficult to distinguish them from each other [79]. Being aware of this limitation, we conducted our study comparing cells at different maturation stages and using a pharmacological dissection tool (ivabradine) in order to functionally discriminate between working myocardium and sinoatrial node cardiomyocytes. Many pieces of evidence support our conclusion that persistent *Isl1* expression in differentiating cardiomyocytes indeed differentially regulates myocyte lineage specification rather than simply delays maturation. The permanent higher expression level of nodal markers and failure of *Isl1OE* cardiomyocytes to upregulate working-myocardium genes even at day 21 of in vitro differentiation—which corresponds to a terminally differentiated state—argues against a mere block of maturation (Fig. 6A). This is further supported by the observation that *Isl1OE* EBs started to beat earlier than their control counterparts (Fig. 5A) and showed well-organized sarcomeres (Supporting Information Fig. S10), indicating that cardiomyocyte maturation is not delayed. Most importantly, the high-throughput AP phenotyping and the pharmacological dissection approaches allowed us to test for cardiomyocyte functionality, evaluate statistical differences in cardiac subtype prevalence, and investigate changes in expression levels of specifically upregulated nodal markers, such as Hcn channels, in single *Isl1OE* ESC-derived cardiomyocytes. All together, our results indicate that maintained *Isl1* expression does not alter electrophysiological properties of cardiomyocytes but rather assures the establishment of the nodal phenotype at the expense of the ventricular lineage.

Notably, it has been recently reported that treatment of differentiating murine ESCs with 1-ethyl-2-benzimidazolinone

(EBIO), an activator of Ca²⁺-activated potassium channels of small and intermediate conductance, enriches for pacemaker-specific gene expression, while suppressing ventricular-specific genes [80]. Interestingly, application of EBIO increased *Isl1* expression in the EB culture. Thus, EBIO-mediated stimulation of the pacemaker gene program is likely to be induced by *Isl1* itself. An analogous function of *Isl1* in establishing a subtype cell identity has been reported for motor neurons and retinal horizontal cells [81–85].

Growing evidence suggests that *Isl1* expression persists in a small set of differentiated myocytes in fetal and adult hearts [86–90]. These cardiomyocytes coexpress *Hcn4*, are localized in the SAN region [86, 88], and derive from *Isl1*-expressing progenitors, as demonstrated by lineage tracing experiments [26, 87]. Moreover, studies in zebrafish indicated a critical role of *Isl1* in pacemaker function [91, 92]. *Isl1* was identified as a *Shox2* downstream target gene and rescued *Shox2*-mediated bradycardia in zebrafish [67]. It is therefore possible that *Isl1* exerts a similar role in pacemaker cells of the mammalian heart as well.

Several approaches using pharmacological treatment have been undertaken to generate SAN cells from ESCs, including EBIO, suramin, and anti-*NRG-1β* [34, 80, 93]. All compounds led to an enrichment of *Hcn4* alongside with *Tbx3* and/or *Tbx2*, which are key regulators of SAN development [40, 94–96]. *Tbx3* has been shown to impose pacemaker function on both embryonic atrial myocytes and adult terminally differentiated working cardiomyocytes [95, 97]. An overlapping expression pattern of *Tbx2* and *Tbx3* during early cardiac development and functional equivalence in repressing markers of working myocardial differentiation, such as *Nppa* and *Cx40*, has been demonstrated [39, 40, 94]. Our data suggest that in *Isl1OE* cardiomyocytes *Tbx2* rather than *Tbx3* is implicated in the suppression of chamber-specific genes *Nppa* and *Cx40*, since only *Tbx2* was upregulated in *Isl1OE* cells.

CONCLUSIONS

In summary, our findings from *Nkx2-5*- and *Isl1*-overexpressing mouse ESCs as well as conditional *Nkx2-5* knockout and *Isl1*-gain-of-function mouse and *Xenopus* models suggest a repressive role of *Nkx2-5* on *Isl1* expression, which may act as a

molecular switch that determines cardiomyocyte lineage fate. These results provide novel insights into cardiac specialization and may be useful for directing cardiomyocyte in vitro differentiation toward specific subpopulations for disease modeling or regenerative approaches.

ACKNOWLEDGMENTS

We thank Kenneth R. Chien (Karolinska Institute) for providing *Nkx2-5^{fl/fl}* mice and Sylvia Evans (University of California-San Diego) for providing *Isl1-Cre* mice as well as fruitful discussion. We acknowledge Diana Grewe, Christina Scherb, Birgit Campbell, and Petra Dietmann for their technical assistance.

This work was supported by grants from the European Research Council, MEXT-23208 and ERC 261053 (K.-L.L.); the German Research Foundation, Research Unit 923, Mo 2217/1-1 (A.M.), La 1238 3-1/4-1/4-2 (K.-L.L.); Si 1747/1-1 (D.S.); Ku 1166/3-2 (M.K.); GSC270 (F.H., M.K., Y.G.); European Social Fund and State of Baden-Württemberg (Eliteprogram for post-docs and MvW scholarship to K.B.); German Centre for Cardiovascular Research (K.-L.L. and A.M.); Federal Ministry of Education and Research, “CordiLux” (P.L.); HOMFORExzellent (Exzellente junge PostDocs-Programm der Medizinischen Fakultät to Q.T.).

AUTHOR CONTRIBUTIONS

T.D., A.G., and J.T.L.: collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript; J.H., Q.T., F.H., K.B., G.D., Y.G., and S.J.K.: collection and assembly of data and final approval of manuscript; M.S.: collection of data and final approval of the manuscript; R.D.: manuscript writing and final approval of the manuscript; D.S. data analysis and interpretation, manuscript writing, financial support, and final approval of the manuscript; P.L., K.-L.L., M.K., and A.M.: conception and design, data analysis and interpretation, manuscript writing, financial support, and final approval of manuscript. T.D., A.G., and J.T.L. contributed equally to this article.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors declare no competing financial interests.

REFERENCES

- Laugwitz K-L, Moretti A, Caron L, et al. *Isl1* cardiovascular progenitors: A single source for heart lineages? *Development* 2008;135(2):193–205.
- Vincent SD, Buckingham ME. How to make a heart: The origin and regulation of cardiac progenitor cells. *Curr Top Dev Biol* 2010;90:1–41.
- Cai C-L, Liang X, Shi Y et al. *Isl1* identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. *Dev Cell* 2003;5(6):877–889.
- Prall OWJ, Menon MK, Solloway MJ et al. An *Nkx2-5/Bmp2/Smad1* negative feedback loop controls heart progenitor specification and proliferation. *Cell* 2007;128(5):947–959.
- Ma Q, Zhou B, Pu WT. Reassessment of *Isl1* and *Nkx2-5* cardiac fate maps using a *Gata4*-based reporter of *Cre* activity. *Dev Biol* 2008;323(1):98–104.
- Moretti A, Caron L, Nakano A et al. Multipotent embryonic *Isl1*⁺ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. *Cell* 2006;127(6):1151–1165.
- Wu SM, Fujiwara Y, Cibulsky SM et al. Developmental origin of a bipotential myocardial and smooth muscle cell precursor in the mammalian heart. *Cell* 2006;127(6):1137–1150.
- Lyons I, Parsons LM, Hartley L et al. Myogenic and morphogenetic defects in the heart tubes of murine embryos lacking the homeo box gene *Nkx2-5*. *Genes Dev* 1995; 9(13):1654–1666.
- Kasahara H, Bartunkova S, Schinke M et al. Cardiac and extracardiac expression of *Csx/Nkx2.5* homeodomain protein. *Circ Res* 1998;82(9):936–946.
- Lints TJ, Parsons LM, Hartley L et al. *Nkx-2.5*: A novel murine homeobox gene expressed in early heart progenitor cells and their myogenic descendants. *Development* 1993;119(2):419–431.
- Pashmforoush M, Lu JT, Chen H et al. *Nkx2-5* pathways and congenital heart disease; loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block. *Cell* 2004; 117(3):373–386.
- Yang L, Cai C-L, Lin L, et al. *Isl1Cre* reveals a common *Bmp* pathway in heart and limb. *Development* 2006;133(8):1575–1585.
- Nieuwkoop PD, Faber J. *Normal Table of Xenopus laevis* (Daudin). 2nd ed. Amsterdam,

The Netherlands: North-Holland Publishing Company, 1967.

- 14** Brade T, Gessert S, Kühl M et al. The amphibian second heart field: *Xenopus* islet-1 is required for cardiovascular development. *Dev Biol* 2007;311(2):297–310.
- 15** Gessert S, Kühl M. Comparative gene expression analysis and fate mapping studies suggest an early segregation of cardiogenic lineages in *Xenopus laevis*. *Dev Biol* 2009;334(2):395–408.
- 16** Gessert S, Maurus D, Rössner A et al. Pescadillo is required for *Xenopus laevis* eye development and neural crest migration. *Dev Biol* 2007;310(1):99–112.
- 17** Herrmann F, Bundschu K, Kühl SJ et al. Tbx5 overexpression favors a first heart field lineage in murine embryonic stem cells and in *Xenopus laevis* embryos. *Dev Dyn* 2011;240(12):2634–2645.
- 18** Witzel HR, Jungblut B, Choe CP et al. The LIM protein Ajuba restricts the second heart field progenitor pool by regulating Isl1 activity. *Dev Cell* 2012;23(1):58–70.
- 19** Wei C-L, Wu Q, Vega VB et al. A global map of p53 transcription-factor binding sites in the human genome. *Cell* 2006;124(1):207–219.
- 20** Black BL. Transcriptional pathways in second heart field development. *Semin Cell Dev Biol* 2007;18(1):67–76.
- 21** Kispert A, Vainio S, Shen L et al. Proteoglycans are required for maintenance of Wnt-11 expression in the ureter tips. *Development* 1996;122(11):3627–3637.
- 22** Kelly RG, Brown NA, Buckingham ME. The arterial pole of the mouse heart forms from Fgf10-expressing cells in pharyngeal mesoderm. *Dev Cell* 2001;1(3):435–440.
- 23** Watanabe Y, Miyagawa-Tomita S, Vincent SD et al. Role of mesodermal FGF8 and FGF10 overlaps in the development of the arterial pole of the heart and pharyngeal arch arteries. *Circ Res* 2010;106(3):495–503.
- 24** Bruneau BG, Logan M, Davis N et al. Chamber-specific cardiac expression of Tbx5 and heart defects in Holt-Oram syndrome. *Dev Biol* 1999;211(1):100–108.
- 25** Liberatore CM, Searcy-Schrick RD, Yutzey KE. Ventricular expression of tbx5 inhibits normal heart chamber development. *Dev Biol* 2000;223(1):169–180.
- 26** Liang X, Wang G, Lin L et al. HCN4 dynamically marks the first heart field and conduction system precursors. *Circ Res* 2013;113(4):399–407.
- 27** Später D, Abramczuk MK, Buac K et al. A HCN4+ cardiomyogenic progenitor derived from the first heart field and human pluripotent stem cells. *Nat Cell Biol* 2013;15(9):1098–1106.
- 28** Choi K, Kennedy M, Kazarov A et al. A common precursor for hematopoietic and endothelial cells. *Development* 1998;125(4):725–732.
- 29** Kattman SJ, Huber TL, Keller GM. Multipotent flk-1+ cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages. *Dev Cell* 2006;11(5):723–732.
- 30** Caprioli A, Koyano-Nakagawa N, Iacovino M et al. Nkx2-5 represses Gata1 gene expression and modulates the cellular fate of cardiac progenitors during embryogenesis. *Circulation* 2011;123(15):1633–1641.
- 31** Simões FC, Peterkin T, Patient R. Fgf differentially controls cross-antagonism between cardiac and haemangioblast regulators. *Development* 2011;138(15):3235–3245.
- 32** Laugwitz K-L, Moretti A, Lam J et al. Postnatal Isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. *Nature* 2005;433(7026):647–653.
- 33** Cambier L, Plate M, Sucov HM et al. Nkx2-5 regulates cardiac growth through modulation of Wnt signaling by R-spondin3. *Development* 2014;141(15):2959–2971.
- 34** Zhu W-Z, Xie Y, Moyes KW et al. Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells. *Circ Res* 2010;107(6):776–786.
- 35** Schram G, Pourrier M, Melnyk P et al. Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. *Circ Res* 2002;90(9):939–950.
- 36** Shi W, Wymore R, Yu H et al. Distribution and prevalence of hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues. *Circ Res* 1999;85(1):e1–e6.
- 37** Bohn G, Moosmang S, Conrad H et al. Expression of T- and L-type calcium channel mRNA in murine sinoatrial node. *FEBS Lett* 2000;481(1):73–76.
- 38** Marionneau C, Couette B, Liu J, et al. Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart. *J Physiol* 2005;562(Pt 1):223–234.
- 39** Habets PEMH, Moorman AFM, Clout DEW et al. Cooperative action of Tbx2 and Nkx2.5 inhibits ANF expression in the atrioventricular canal: Implications for cardiac chamber formation. *Genes Dev* 2002;16(10):1234–1246.
- 40** Christoffels VM, Hoogaars WMH, Tessari A et al. T-box transcription factor Tbx2 represses differentiation and formation of the cardiac chambers. *Dev Dyn* 2004;229(4):763–770.
- 41** Bao ZZ, Bruneau BG, Seidman JG et al. Regulation of chamber-specific gene expression in the developing heart by Irx4. *Science* 1999;283(5405):1161–1164.
- 42** Bruneau BG, Bao ZZ, Fatkin D, et al. Cardiomyopathy in Irx4-deficient mice is preceded by abnormal ventricular gene expression. *Mol Cell Biol* 2001;21(5):1730–1736.
- 43** Koibuchi N, Chin MT. CHF1/Hey2 plays a pivotal role in left ventricular maturation through suppression of ectopic atrial gene expression. *Circ Res* 2007;100(6):850–855.
- 44** Xin M, Small EM, van Rooij E et al. Essential roles of the bHLH transcription factor Hrt2 in repression of atrial gene expression and maintenance of postnatal cardiac function. *Proc Natl Acad Sci USA* 2007;104(19):7975–7980.
- 45** O'Brien TX, Lee KJ, Chien KR. Positional specification of ventricular myosin light chain 2 expression in the primitive murine heart tube. *Proc Natl Acad Sci USA* 1993;90(11):5157–5161.
- 46** Ng SY, Wong CK, Tsang SY. Differential gene expressions in atrial and ventricular myocytes: Insights into the road of applying embryonic stem cell-derived cardiomyocytes for future therapies. *Am J Physiol Cell Physiol* 2010;299(6):C1234–C1249.
- 47** Jansen JA, van Veen TAB, de Bakker JMT et al. Cardiac connexins and impulse propagation. *J Mol Cell Cardiol* 2010;48(1):76–82.
- 48** Christoffels VM, Habets PE, Franco D et al. Chamber formation and morphogenesis in the developing mammalian heart. *Dev Biol* 2000;223(2):266–278.
- 49** Houweling AC, van Borren MM, Moorman AFM et al. Expression and regulation of the atrial natriuretic factor encoding gene Nppa during development and disease. *Cardiovasc Res* 2005;67(4):583–593.
- 50** Mori AD, Zhu Y, Vahora I et al. Tbx5-dependent rheostatic control of cardiac gene expression and morphogenesis. *Dev Biol* 2006;297(2):566–586.
- 51** Gittenberger-de Groot AC, Mahtab EAF, Hahurij ND et al. Nkx2.5-negative myocardium of the posterior heart field and its correlation with podoplanin expression in cells from the developing cardiac pacemaking and conduction system. *Anat Rec (Hoboken)* 2007;290(1):115–122.
- 52** Stieber J, Herrmann S, Feil S et al. The hyperpolarization-activated channel HCN4 is required for the generation of pacemaker action potentials in the embryonic heart. *Proc Natl Acad Sci USA* 2003;100(25):15235–15240.
- 53** Tian Q, Oberhofer M, Ruppenthal S et al. Optical action potential screening on adult ventricular myocytes as an alternative QT-screen. *Cell Physiol Biochem* 2011;27(3-4):281–290.
- 54** Müller O, Tian Q, Zantl R et al. A system for optical high resolution screening of electrical excitable cells. *Cell Calcium* 2010;47(3):224–233.
- 55** Leyton-Mange JS, Mills RW, Macri VS et al. Rapid cellular phenotyping of human pluripotent stem cell-derived cardiomyocytes using a genetically encoded fluorescent voltage sensor. *Stem Cell Rep* 2014;2(2):163–170.
- 56** Lopez-Izquierdo A, Warren M, Riedel M et al. A near-infrared fluorescent voltage-sensitive dye allows for moderate-throughput analyses of human induced pluripotent stem cell-derived cardiomyocytes. *Am J Physiol Heart Circ Physiol* 2014;307:H1370–H1377.
- 57** Wobus AM, Rohwedel J, Maltsev V et al. Development of cardiomyocytes expressing cardiac-specific genes, action potentials, and ionic channels during embryonic stem cell-derived cardiogenesis. *Ann N Y Acad Sci* 1995;752:460–469.
- 58** Moretti A, Bellin M, Welling A et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. *N Engl J Med* 2010;363(15):1397–1409.
- 59** Bucchi A, Tognati A, Milanese R et al. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. *J Physiol* 2006;572(Pt 2):335–346.
- 60** Wang P, Tang M, Gao L et al. Roles of I(f) and intracellular Ca²⁺ release in spontaneous activity of ventricular cardiomyocytes during murine embryonic development. *J Cell Biochem* 2013;114(8):1852–1862.
- 61** Bucchi A, Baruscotti M, DiFrancesco D. Current-dependent block of rabbit sino-atrial

- node I(f) channels by ivabradine. *J Gen Physiol* 2002;120(1):1–13.
- 62** Semmler J, Lehmann M, Pfannkuche K et al. Functional expression and regulation of hyperpolarization-activated cyclic nucleotide-gated channels (HCN) in mouse iPS cell-derived cardiomyocytes after UTF1-neo selection. *Cell Physiol Biochem* 2014;34(4):1199–1215.
- 63** David R, Stieber J, Fischer E et al. Forward programming of pluripotent stem cells towards distinct cardiovascular cell types. *Cardiovasc Res* 2009;84(2):263–272.
- 64** Baruscotti M, Barbuti A, Bucchi A. The cardiac pacemaker current. *J Mol Cell Cardiol* 2010;48(1):55–64.
- 65** Liao J, Aggarwal VS, Nowotschin S et al. Identification of downstream genetic pathways of Tbx1 in the second heart field. *Dev Biol* 2008;316(2):524–537.
- 66** Park EJ, Ogden LA, Talbot A et al. Required, tissue-specific roles for Fgf8 in outflow tract formation and remodeling. *Development* 2006;133(12):2419–2433.
- 67** Hoffmann S, Berger IM, Glaser A et al. Islet1 is a direct transcriptional target of the homeodomain transcription factor Shox2 and rescues the Shox2-mediated bradycardia. *Basic Res Cardiol* 2013;108(2):339.
- 68** Kang J, Nathan E, Xu S-M et al. Is1 is a direct transcriptional target of Forkhead transcription factors in second-heart-field-derived mesoderm. *Dev Biol* 2009;334(2):513–522.
- 69** Kappen C, Salbaum JM. Identification of regulatory elements in the Is1 gene locus. *Int J Dev Biol* 2009;53(7):935–946.
- 70** Liu Y, Li Y, Li T et al. POU homeodomain protein OCT1 modulates islet 1 expression during cardiac differentiation of P19CL6 cells. *Cell Mol Life Sci* 2011;68(11):1969–1982.
- 71** Cai C-L, Zhou W, Yang L et al. T-box genes coordinate regional rates of proliferation and regional specification during cardiogenesis. *Development* 2005;132(10):2475–2487.
- 72** Watanabe Y, Zaffran S, Kuroiwa A et al. Fibroblast growth factor 10 gene regulation in the second heart field by Tbx1, Nkx2-5, and Islet1 reveals a genetic switch for down-regulation in the myocardium. *Proc Natl Acad Sci USA* 2012;109(45):18273–18280.
- 73** Brade T, Pane LS, Moretti A et al. Embryonic heart progenitors and cardiogenesis. *Cold Spring Harb Perspect Med* 2013;3(10):a013847.
- 74** Wang R, Liang J, Jiang H, et al. Promoter-dependent EGFP expression during embryonic stem cell propagation and differentiation. *Stem Cells Dev* 2008;17(2):279–289.
- 75** Pandur P, Sirbu IO, Kühl SJ et al. Islet1-expressing cardiac progenitor cells: A comparison across species. *Dev Genes Evol* 2013;223(1-2):117–129.
- 76** Mann T, Bodmer R, Pandur P. The Drosophila homolog of vertebrate Islet1 is a key component in early cardiogenesis. *Development* 2009;136(2):317–326.
- 77** Kwon C, Qian L, Cheng P et al. A regulatory pathway involving Notch1/beta-catenin/Is1 determines cardiac progenitor cell fate. *Nat Cell Biol* 2009;11(8):951–957.
- 78** Bondue A, Tännler S, Chiapparo G et al. Defining the earliest step of cardiovascular progenitor specification during embryonic stem cell differentiation. *J Cell Biol* 2011;192(5):751–765.
- 79** Hescheler J, Fleischmann BK, Lentini S et al. Embryonic stem cells: A model to study structural and functional properties in cardiomyogenesis. *Cardiovasc Res* 1997;36(2):149–162.
- 80** Kleger A, Seufferlein T, Malan D et al. Modulation of calcium-activated potassium channels induces cardiogenesis of pluripotent stem cells and enrichment of pacemaker-like cells. *Circulation* 2010;122(18):1823–1836.
- 81** Pfaff SL, Mendelsohn M, Stewart CL et al. Requirement for LIM homeobox gene Is1 in motor neuron generation reveals a motor neuron-dependent step in interneuron differentiation. *Cell* 1996;84(2):309–320.
- 82** Shirasaki R, Pfaff SL. Transcriptional codes and the control of neuronal identity. *Annu Rev Neurosci* 2002;25:251–281.
- 83** Thaler JP, Lee S-K, Jurata LW et al. LIM factor Lhx3 contributes to the specification of motor neuron and interneuron identity through cell-type-specific protein-protein interactions. *Cell* 2002;110(2):237–249.
- 84** Tsuchida T, Ensinini M, Morton SB et al. Topographic organization of embryonic motor neurons defined by expression of LIM homeobox genes. *Cell* 1994;79(6):957–970.
- 85** Suga A, Taira M, Nakagawa S. LIM family transcription factors regulate the subtype-specific morphogenesis of retinal horizontal cells at post-migratory stages. *Dev Biol* 2009;330(2):318–328.
- 86** Mommersteeg MTM, Hoogaars WMH, Prall OWJ et al. Molecular pathway for the localized formation of the sinoatrial node. *Circ Res* 2007;100(3):354–362.
- 87** Mommersteeg MTM, Domínguez JN, Wiese C et al. The sinus venosus progenitors separate and diversify from the first and second heart fields early in development. *Cardiovasc Res* 2010;87(1):92–101.
- 88** Sun Y, Liang X, Najafi N et al. Islet 1 is expressed in distinct cardiovascular lineages, including pacemaker and coronary vascular cells. *Dev Biol* 2007;304(1):286–296.
- 89** Khattar P, Friedrich FW, Bonne G et al. Distinction between two populations of islet-1-positive cells in hearts of different murine strains. *Stem Cells Dev* 2011;20(6):1043–1052.
- 90** Weinberger F, Mehrkens D, Friedrich FW et al. Localization of Islet-1-positive cells in the healthy and infarcted adult murine heart. *Circ Res* 2012;110(10):1303–1310.
- 91** Tessadori F, van Weerd JH, Burkhard SB et al. Identification and functional characterization of cardiac pacemaker cells in zebrafish. *PLoS ONE* 2012;7(10):e47644.
- 92** de Pater E, Clijsters L, Marques SR et al. Distinct phases of cardiomyocyte differentiation regulate growth of the zebrafish heart. *Development* 2009;136(10):1633–1641.
- 93** Wiese C, Nikolova T, Zahanich I et al. Differentiation induction of mouse embryonic stem cells into sinus node-like cells by suramin. *Int J Cardiol* 2011;147(1):95–111.
- 94** Hoogaars WMH, Tessari A, Moorman AFM et al. The transcriptional repressor Tbx3 delineates the developing central conduction system of the heart. *Cardiovasc Res* 2004;62(3):489–499.
- 95** Hoogaars WMH, Engel A, Brons JF et al. Tbx3 controls the sinoatrial node gene program and imposes pacemaker function on the atria. *Genes Dev* 2007;21(9):1098–1112.
- 96** Harrelson Z, Kelly RG, Goldin SN et al. Tbx2 is essential for patterning the atrioventricular canal and for morphogenesis of the outflow tract during heart development. *Development* 2004;131(20):5041–5052.
- 97** Bakker ML, Boink GJJ, Boukens BJ et al. T-box transcription factor TBX3 reprograms mature cardiac myocytes into pacemaker-like cells. *Cardiovasc Res* 2012;94(3):439–449.



See www.StemCells.com for supporting information available online.